Christian S. Frandsen

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

Thomas F. Dejgaard, Christian S. Frandsen, Tanja Sofie Hansen et al. · The Lancet Diabetes & Endocrinology · 2015 · 167 citations

Obesity, Metabolic Syndrome, Type 1 +6

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study

Christian S. Frandsen, Thomas F. Dejgaard, Jens J. Holst et al. · Diabetes Care · 2015 · 99 citations

Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy

Jacob Uth, Therese Hornstrup, Jakob Friis Schmidt et al. · Scandinavian Journal of Medicine and Science in Sports · 2014 · 86 citations

Physical Activity, Exercise Oncology, Kinesiology +16

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial

Thomas F. Dejgaard, Signe Schmidt, Christian S. Frandsen et al. · Diabetes Obesity and Metabolism · 2019 · 63 citations

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial

Nicklas J. Johansen, Thomas F. Dejgaard, Asger Lund et al. · The Lancet Diabetes & Endocrinology · 2020 · 61 citations

Nutrition, Type 1, Short-acting Exenatide +9